ClinicalTrials.gg
Not yet recruitingNCT07808190Updated Sep 8, 2026

HD-tACS for Alcohol Use Disorder

An interventional study of HD-tACS and Sham HD-tACS in Alcohol Use Disorder, sponsored by Shanghai Mental Health Center. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Alcoholism by Shanghai Mental Health Center — 4 open to participants now, 5 under way, none of them phase 3. Alcoholism · Shanghai Mental Health Center.

Planned enrollment
3rd of 12
140 · median 60
Started
2026
with 2 others
No phase
12 of 12
4 open now
Registered
12th of 12
by date

Among the 12 studies in Alcoholism by Shanghai Mental Health Center, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2026, is one of 12 with no phase, and was the 12th registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

4 of the 12 studies in Alcoholism by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Alcoholism by Shanghai Mental Health Center, or all of them as a file.
02

Study summary

This study aims to systematically explore the effectiveness of accelerated HD-tACS in treating AUD, particularly its efficacy in reducing alcohol craving and preventing relapse in AUD patients.

Read the detailed description

This study conducted a multi-center randomized clinical controlled trial among individuals with alcohol use disorders, aiming to verify the effectiveness of accelerated HD-tACS in targeting the dorsolateral prefrontal cortex for the treatment of AUD. In particular, it aimed to assess the efficacy of accelerated HD-tACS in reducing alcohol craving and reducing relapse. Eligible patients were randomly divided into the accelerated HD-tACS group and the sham stimulation group in a 1:1 ratio. Clinical and electroencephalogram data were collected at baseline and after the intervention. Additionally, a follow-up assessment of alcohol consumption was conducted for all participants after the intervention ended.

03

Conditions studied

  • Alcohol Use Disorder

Browse trials for

Keywords

  • alcohol use disorder
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age range: 18-55 years old, gender not restricted;
  • Meets the diagnostic criteria for alcohol use disorder (moderate to severe);
  • AUDIT score ≥ 16;
  • Baseline score after alcohol cue-induced stimulation is ≥ 3;
  • Completed detoxification treatment before enrollment (moderate to severe), with detoxification duration of ≥ 7 days and ≤ 90 days;
  • Has a primary school education or above, and can understand and complete the research assessment;
  • Voluntarily participated in the study and signed the form.

Exclusion criteria

Exclusion Criteria:

  • Currently, there are other substance use disorders (except nicotine);
  • Currently, there are schizophrenia, bipolar disorder or other severe psychotic disorders;
  • Has a history of epilepsy or family history of epilepsy;
  • Has a history of brain trauma, brain surgery or intracranial metal implants;
  • Has received electroconvulsive therapy (ECT), transcranial electrical/magnetic/ultrasound stimulation within the past 6 months;
  • Pregnant or lactating women;
  • Other situations that the researchers consider unsuitable for participation in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    HD-tACS group

    Using the transcranial electrical stimulation device, with the ring-shaped focusing technology, the current is locked in the target area through a 4\*1 electrode configuration, causing the peak to appear below the central electrode.

    Device: HD-tACS

  • Sham comparator
    Sham HD-tACS group

    Using the transcranial electrical stimulation device, with the ring-shaped focusing technology, the current is locked in the target area through a 4\*1 electrode configuration, causing the peak to appear below the central electrode.

    Device: Sham HD-tACS

Interventions

  • DeviceHD-tACS

    The stimulation parameters are 40Hz and 2mA. The stimulation protocol is 20 minutes per session, 3 times per day, for a total of 10 consecutive days.

  • DeviceSham HD-tACS

    The stimulation parameters are 40Hz and 2mA. The stimulation protocol is 20 minutes per session, 3 times per day, for a total of 10 consecutive days. At the commencement and conclusion of each therapeutic session, a 30-second ramp-up stimulation and a 30-second ramp-down stimulation (totaling 60 seconds) are administered, respectively, while the current output of the device is maintained at zero throughout the intervening interval.

06

What researchers measure

Primary outcomes

  1. Change of Craving

    Visual Analog Scale, range 0-100 point, the higher the score, the more one wants drugs.

    Time frame: baseline; The 2nd, 4th, 6th, 8th and 10th days during the intervention period; 4 weeks after treatment; 12 weeks after treatment

Secondary outcomes

  1. impulsivity

    Stop Single Task

    Time frame: baseline; 1 day after the treatment was completed

  2. Negative reinforcement learning task

    The negative reinforcement learning task was adopted to evaluate the patients' avoidance-avoidance behaviors and learning. By calculating and modeling, the avoidance-avoidance behavior bias (active avoidance bias ) and the learning rates based on different feedback: learning from successfully avoiding the aversive stimulus; learning from experiencing the aversive stimulus) were constructed.

    Time frame: baseline; 1 day after treatment was completed

  3. Changes in Reward Learning

    Reward Learning Task

    Time frame: baseline; 1 day after treatment was completed

  4. Compulsory drinking

    The Obsessive Compulsive Drinking Scale (OCDS) assesses compulsive thoughts and impulsive behaviors related to alcohol consumption. It consists of 14 items, each rated on a 5-point scale from 0 to 4. Scores ranging from 0 to 14 indicate almost no compulsive drinking characteristics, 15 to 28 indicate obvious compulsive thoughts or impulses, and scores above 29 indicate a significant compulsive drinking pattern with a high risk of relapse.

    Time frame: baseline; 1 day after treatment was completed

  5. Depressive state

    The depression assessment was conducted using the Patient Health Questionnaire - 9 (PHQ-9), which consists of 9 items, each representing a different aspect of depressive symptoms. Each item is scored on a 4-point scale. 0-4 points indicate no depressive symptoms, 5-9 points represent mild depression, 10-14 points indicate moderate depression, and scores above 15 indicate severe depression.

    Time frame: baseline; 1 day after treatment was completed

  6. Anxiety state

    The anxiety assessment was conducted using the Generalized Anxiety Disorder - 7 (GAD-7) self-rating scale. The core statistical indicator of this scale is the total score. The higher the score, the more severe the anxiety. A total score of 0-4 indicates no anxiety or the anxiety level is not clinically significant; a score of 5-9 represents mild anxiety; a score of 10-14 indicates moderate anxiety; and a score of 15 or above indicates severe anxiety.

    Time frame: baseline; 1 day after treatment was completed;

  7. Sleeping conditions

    The assessment was conducted using the Pittsburgh Sleep Quality Index (PSQI), with the total score ranging from 0 to 21. A higher score indicates poorer sleep quality.

    Time frame: baseline; 1 day after the treatment was completed

  8. EEG

    EEG features such as event-related potentials (ERPs) and power spectral density (e.g., theta or alpha power)

    Time frame: baseline; 1 day after treatment was completed

  9. EEG

    change of functional connection of brain area

    Time frame: baseline; 1 day after treatment was completed

  10. use of alcohol

    Simple questionnaire to collect alcohol consumption and drinking frequency.

    Time frame: 4 weeks after treatment; 12 weeks after treatment

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.

Of 470 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's planned 3 months is below that.

Counting every sponsor, half of 493 studies reached it within 33 months; a quarter within 17 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2026
First posted
Sep 8, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07808190
Responsible party
Sponsor
First posted
Sep 8, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 8, 2026

Study contacts

Haifeng Jiang
Contact
dragonjhf@hotmail.com
64387250
Tianzhen Chen
Contact
vomchan@hotmail.com
64387250
Min Zhao
study chair · Shanghai Mental Health Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion